Clinical Trial Update: A Phase I/II Open Label Extension Study of BIBF 1120 Administered Orally Once or Twice Daily to Establish Safety, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumours and Clinical Benefit From Previous Therapy With BIBF 1120 [Phase 1]

View source ↗

Summary

This clinical trial update reports results from an open-label Phase I/II extension study of BIBF 1120 (nintedanib) in patients with advanced solid tumors who pr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neoplasms

Drugs mentioned

• BIBF 1120 (nintedanib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Neoplasms | Phase 1 | Status: COMPLETED | Results posted: 2014-12-02